Compile Data Set for Download or QSAR
maximum 50k data
Found 295 Enz. Inhib. hit(s) with all data for entry = 10326
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528106(N-{[5-methoxy-2-(1,2,3,4-tetrazol-1-yl)phenyl]meth...)
Affinity DataKi:  0.100nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528123(N-{[5-chloro-2-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataKi:  0.160nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataKi:  0.170nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataKi:  0.230nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528105(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataKi:  0.260nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528131(1-{[2-(3,3-Difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataKi:  0.280nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528119(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataKi:  0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataKi:  0.380nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528074(N-{[2-Fluoro-6-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataKi:  0.520nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528130(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataKi:  0.530nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528094(N-[(4-methoxy-3-methylpyridin-2-yl)methyl]-3-(meth...)
Affinity DataKi:  1.90nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528129(N-{[5-methoxy-2-(1,2,3,4-tetrazol-1-yl)phenyl]meth...)
Affinity DataKi:  2.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataKi:  2.90nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408666(3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]...)
Affinity DataKi:  6.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528077(N-i6-chloro-2-fluoro-3-methoxybenzyl)-1 -ii2-methy...)
Affinity DataKi:  139nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 18...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528130(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50:  0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528122(3-amino-N-{[5-chloro-2-(1,2,3,4-tetrazol-1-yl)phen...)
Affinity DataIC50:  0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528106(N-{[5-methoxy-2-(1,2,3,4-tetrazol-1-yl)phenyl]meth...)
Affinity DataIC50:  0.400nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528108(N-[(6-carbamoyl-2-fluoro-3-methoxyphenyl)methyl]-3...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(me...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528105(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528121(N-{[2-fluoro-6-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528123(N-{[5-chloro-2-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataIC50:  0.700nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528132(1-{[6-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl]me...)
Affinity DataIC50:  0.800nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528119(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50:  0.900nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528074(N-{[2-Fluoro-6-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataIC50:  1.10nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM455297(US10730874, Compound TABLE II.2 | US11180484, Exam...)
Affinity DataIC50:  1.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  1.5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528131(1-{[2-(3,3-Difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50:  1.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528102(3-amino-N-[(2,6-difluoro-3-methoxyphenyl)methyl]-1...)
Affinity DataIC50:  1.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528116(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-1-({4...)
Affinity DataIC50:  1.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528120(N-{[5-methoxy-2-(1,2,3,4-tetrazol-1-yl)phenyl]meth...)
Affinity DataIC50:  1.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528127(US11180484, Example 79 | US11180484, Reference Exa...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528083(3-amino-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50:  3.20nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528108(N-[(6-carbamoyl-2-fluoro-3-methoxyphenyl)methyl]-3...)
Affinity DataIC50:  3.60nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528094(N-[(4-methoxy-3-methylpyridin-2-yl)methyl]-3-(meth...)
Affinity DataIC50:  4.90nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528115(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(me...)
Affinity DataIC50:  6.40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50:  6.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408775( N-{[2-(difluoromethyl)-6-fluoro-3-methoxyphenyl]m...)
Affinity DataIC50:  6.80nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528133(1-{[2-(3,3-difluoropyrrolidin-1-yl)pyrimidin-5-yl]...)
Affinity DataIC50:  8.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408666(3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]...)
Affinity DataIC50:  8.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528110(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(di...)
Affinity DataIC50:  8.80nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528129(N-{[5-methoxy-2-(1,2,3,4-tetrazol-1-yl)phenyl]meth...)
Affinity DataIC50:  10.6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528111(N-{[5-fluoro-2-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataIC50:  15.9nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528125(3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl...)
Affinity DataIC50:  17.6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528085(3-(dimethylamino)-N-[(3-fluoro-4-methoxypyridin-2-...)
Affinity DataIC50:  18nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528113(N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(me...)
Affinity DataIC50:  21.3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528124(N-{[2-chloro-6-(1,2,3,4-tetrazol-1-yl)phenyl]methy...)
Affinity DataIC50:  23.1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 295 total ) | Next | Last >>
Jump to: